Ardelyx (ARDX) Price & Analysis

Compare

1,790 Followers

ARDX Stock Chart & Stats

$5.80

-$0.17(-3.14%)

At close: Jan 08 4:00 PM EST

$5.80

-$0.17(-3.14%)

Day’s Range― - ―

52-Week Range$3.21 - $6.78

Previous CloseN/A

Volume1.36M

Average Volume (3M)2.79M

Market Cap

$1.42B

Enterprise Value$1.30B

Total Cash (Recent Filing)$242.71M

Total Debt (Recent Filing)$207.61M

Price to Earnings (P/E)―

Beta0.82

Next Earnings

Mar 11, 2026

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding242,974,300

10 Day Avg. Volume3,110,692

30 Day Avg. Volume2,791,309

Financial Highlights & Ratios

PEG Ratio0.70

Price to Book (P/B)6.88

Price to Sales (P/S)3.57

P/FCF Ratio-26.03

Enterprise Value/Market Cap0.91

Enterprise Value/Revenue3.26

Enterprise Value/Gross Profit3.67

Enterprise Value/Ebitda-45.68

Forecast

1Y Price Target

$11.50

Price Target Upside98.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-0.23

Revenue Forecast (FY)$401.34M

Bulls Say, Bears Say

Bulls Say

Guidance IncreaseManagement has raised guidance for Ibsrela's revenue, indicating strong confidence in its continued performance.

Market OpportunitiesUp to 50% of patients with IBS-C fail GCC agonists, leaving a white-space opportunity for Ibsrela as a key treatment option.

Revenue GrowthIbsrela remains a primary source of topline and value growth for Ardelyx, supported by its continued commercial success with record quarters in revenue.

Bears Say

Coverage LossXPHOZAH faces challenges due to the loss of Medicare Part D coverage, impacting its commercial environment and requiring adjustments.

Ardelyx News

Ardelyx Announces Key Leadership Transitions

Ardelyx ( ($ARDX) ) has issued an update. Ardelyx, Inc., a company operating in the pharmaceutical or healthcare...

8d ago

ARDX

Ardelyx price target raised to $10 from $9 at Piper Sandler

Piper Sandler raised the firm’s price target on Ardelyx (ARDX) to $10 from $9 and keeps a Neutral...

2M ago

ARDX

Ardelyx files automatic mixed securities shelf

16:52 EST Ardelyx (ARDX) files automatic mixed securities shelf Published first on TheFly – the ultimate source for...

2M ago

ARDX

Ardelyx price target raised to $11 from $10 at Citi

Citi raised the firm’s price target on Ardelyx (ARDX) to $11 from $10 and keeps a Buy rating...

2M ago

ARDX

Ardelyx Inc. Reports Strong Q3 Earnings Growth

Ardelyx Inc (($ARDX)) has held its Q3 earnings call. Read on for the main highlights of the call....

2M ago

ARDX

Midday Fly By: Apple, Amazon upbeat reports lift Nasdaq

The major averages were mostly higher as strong quarterly reports from tech giants Amazon and Apple spurred traders’...

2M ago

Ardelyx price target raised to $10 from $9 at TD Cowen

TD Cowen raised the firm’s price target on Ardelyx (ARDX) to $10 from $9 and keeps a Buy...

2M ago

ARDX

Ardelyx’s Strong Financial Performance and Growth Potential Drive Buy Rating

Analyst Julian Harrison of BTIG reiterated a Buy rating on Ardelyx, retaining the price target of $14.00. Julian...

2M ago

ARDX

Ardelyx’s Strategic Growth and Pipeline Potential Justify Buy Rating

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Ardelyx today and set a price target of...

2M ago

ARDX

Ardelyx Reports Strong Q3 Growth and Pipeline Expansion

Ardelyx Inc ( ($ARDX) ) has released its Q3 earnings. Here is a breakdown of the information Ardelyx...

2M ago

ARDX

Ardelyx’s Strong Market Performance and Growth Potential Justify Buy Rating and Raised Price Target

TD Cowen analyst Joseph Thome maintained a Buy rating on Ardelyx today and set a price target of...

2M ago

ARDX

Ardelyx reports Q3 EPS 0c, consensus (7c)

Reports Q3 revenue $110.33M, consensus $100.54M. “This quarter’s results highlight the growth of our business as we advance...

2M ago

ARDX

Ardelyx presents data on IBSRELA at ACG annual scientific meeting

Ardelyx (ARDX), announced that the company presented data supporting the company’s first-in-class retainagogue, IBSRELA at the American College...

2M ago

ARDX

ARDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Ardelyx Inc (ARDX) is scheduled to report 3rd quarter earnings on 10/30/2025, after the market closes. Regarding Q3...

2M ago

ARDX

ARDX FAQ

What was Ardelyx Inc’s price range in the past 12 months?

Ardelyx Inc lowest stock price was $3.21 and its highest was $6.78 in the past 12 months.

What is Ardelyx Inc’s market cap?

Ardelyx Inc’s market cap is $1.42B.

When is Ardelyx Inc’s upcoming earnings report date?

Ardelyx Inc’s upcoming earnings report date is Mar 11, 2026 which is in 76 days.

How were Ardelyx Inc’s earnings last quarter?

Ardelyx Inc released its earnings results on Oct 30, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.058 by $0.058.

Is Ardelyx Inc overvalued?

According to Wall Street analysts Ardelyx Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ardelyx Inc pay dividends?

Ardelyx Inc does not currently pay dividends.

What is Ardelyx Inc’s EPS estimate?

Ardelyx Inc’s EPS estimate is 0.02.

How many shares outstanding does Ardelyx Inc have?

Ardelyx Inc has 242,974,300 shares outstanding.

What happened to Ardelyx Inc’s price movement after its last earnings report?

Ardelyx Inc reported an EPS of $0 in its last earnings report, beating expectations of -$0.058. Following the earnings report the stock price went up 20.958%.

Which hedge fund is a major shareholder of Ardelyx Inc?

Currently, no hedge funds are holding shares in ARDX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Ardelyx Stock Smart Score

Neutral

Fundamentals

Return on Equity

-36.18%

Trailing 12-Months

Asset Growth

32.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ardelyx Inc

Ardelyx, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with gastrointestinal and renal diseases. The company operates primarily in the healthcare sector and is known for its research and development of novel treatments that target unmet medical needs. Ardelyx's core products include tenapanor, a drug designed to treat patients with irritable bowel syndrome with constipation (IBS-C) and hyperphosphatemia in patients with chronic kidney disease.

Ardelyx (ARDX) Earnings & Revenues

Historic Earnings Reports

ARDX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted Ardelyx's strong financial performance, driven by significant growth in IBSRELA and XPHOZAH revenue. The introduction of a new compound, ARDX-10531, marks a positive step in pipeline development. However, challenges remain, particularly in achieving XPHOZAH's long-term revenue goals amidst market disruptions.View all ARDX earnings summaries

ARDX Stock 12 Month Forecast

Average Price Target

$11.50

▲(98.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","15":"$15","5.25":"$5.25","8.5":"$8.5","11.75":"$11.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,5.25,8.5,11.75,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.06,6.67076923076923,7.281538461538461,7.892307692307693,8.503076923076923,9.113846153846154,9.724615384615385,10.335384615384616,10.946153846153846,11.556923076923077,12.167692307692308,12.778461538461539,13.389230769230771,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.06,6.478461538461538,6.896923076923077,7.315384615384615,7.733846153846153,8.152307692307692,8.57076923076923,8.989230769230769,9.407692307692308,9.826153846153847,10.244615384615384,10.663076923076922,11.081538461538461,{"y":11.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.06,6.363076923076923,6.666153846153846,6.969230769230769,7.272307692307692,7.575384615384616,7.878461538461538,8.181538461538462,8.484615384615385,8.787692307692307,9.090769230769231,9.393846153846154,9.696923076923078,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.09,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.54,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.79,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >